Obsessive-Compulsive Disorder - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 59

Obsessive-Compulsive Disorder – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Obsessive-Compulsive Disorder - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Obsessive-Compulsive Disorder.
- A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Obsessive-Compulsive Disorder Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Obsessive-Compulsive Disorder 8
Obsessive-Compulsive Disorder Therapeutics under Development by Companies 10
Obsessive-Compulsive Disorder Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Obsessive-Compulsive Disorder Therapeutics – Products under Development by Companies 15
Obsessive-Compulsive Disorder Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Obsessive-Compulsive Disorder Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Les Laboratoires Servier 18
Transcept Pharmaceuticals, Inc. 19
Omeros Corporation 20
PharmaNeuroBoost N.V. 21
Obsessive-Compulsive Disorder – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ketamine hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
riluzole - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
riluzole - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ketamine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cognitive Behavioral Therapy + D-Cycloserine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
memantine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
flumazenil - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
acetylcysteine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dronabinol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ketamine hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ondansetron - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PNB-05 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OMS-527 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
agomelatine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
paliperidone palmitate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
immune globulin intravenous (human) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RO-4917838 + Selective Serotonin Reuptake Inhibitors - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Obsessive-Compulsive Disorder Therapeutics – Drug Profile Updates 51
Obsessive-Compulsive Disorder Therapeutics – Discontinued Products 53
Obsessive-Compulsive Disorder Therapeutics - Dormant Products 54
Obsessive-Compulsive Disorder – Product Development Milestones 55
Featured News & Press Releases 55
Sep 12, 2012: Transcept Pharma Completes Patient Enrollment In Phase II Clinical Trial Of TO-2061 Added As Adjunctive Therapy For Obsessive Compulsive Disorder 55
Mar 14, 2011: Transcept Initiates Phase II Study Of TO-2061 55
Oct 01, 2004: IVAX Receives Final Approval on Fluoxetine Tablets and Capsules. 57
Jan 29, 2002: Teva Announces Final Approval for Fluoxetine 10, 20 & 40 mg Capsules 57
Aug 02, 2001: Teva Announces Final Approval of Fluoxetine Oral Solution 57
Jun 03, 2001: Teva Announces Tentative Approval for Fluoxetine 10mg 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Obsessive-Compulsive Disorder, H2 2012 8
Products under Development for Obsessive-Compulsive Disorder – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
F. Hoffmann-La Roche Ltd., H2 2012 17
Les Laboratoires Servier, H2 2012 18
Transcept Pharmaceuticals, Inc., H2 2012 19
Omeros Corporation, H2 2012 20
PharmaNeuroBoost N.V., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Obsessive-Compulsive Disorder Therapeutics – Drug Profile Updates 51
Obsessive-Compulsive Disorder Therapeutics – Discontinued Products 53
Obsessive-Compulsive Disorder Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2012 8
Products under Development for Obsessive-Compulsive Disorder – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Customers who bought this item also bought

• Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H2 2012
• Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2012
• Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives
• Major Depressive Disorder - Pipeline Review, H2 2012
• Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2012
• Gastric Motility Disorder - Pipeline Review, H2 2012
• Lysosomal Storage Disorder - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012